骨膜蛋白在2型糖尿病肾病中的作用研究进展
Research Progress on the Role of Periostin in Type 2 Diabetic Nephropathy
DOI: 10.12677/acm.2026.1662257, PDF,   
作者: 王 欣*：济宁医学院临床医学院，山东 济宁；孙文学：济宁市第一人民医院临床药学科，山东 济宁；马晓庆#：济宁市第一人民医院内分泌科，山东 济宁
关键词: 骨膜蛋白；2型糖尿病肾病；糖脂代谢；纤维化；Periostin； Type 2 Diabetic Kidney Disease； Glucolipid Metabolism； Fibrosis
摘要: 糖尿病肾脏病(Diabetic Kidney Disease, DKD)是2型糖尿病微血管疾病的并发症，是导致终末期肾病(End-Stage Renal Disease, ESRD)的主要诱因，其进展严重损害患者的生活质量，同时对生存预后产生不良影响。目前2型糖尿病肾病的发病机制尚未完全明确，既往的研究多聚焦于糖代谢紊乱、炎症反应、肾素–血管紧张素系统激活以及细胞外基质代谢失衡等。近年研究表明骨膜蛋白(Periostin, POSTN)参与糖脂代谢紊乱、胰岛素抵抗等病理生理过程，与糖尿病相关肾病的发生发展密切相关。综述了骨膜蛋白与2型糖尿病相关肾病之间的关系与机制，以期为DKD的诊治提供新的证据。
Abstract: Diabetic Kidney Disease (DKD) is a microvascular complication of type 2 diabetes mellitus and a leading cause of end-stage renal disease (ESRD). Its progression severely impairs patients’ quality of life and adversely affects survival prognosis. The pathogenesis of type 2 diabetic nephropathy remains incompletely understood. Previous studies have mostly focused on glucose metabolic disorders, inflammatory responses, activation of the renin-angiotensin system, and imbalance in extracellular matrix metabolism. Recent studies have shown that periostin (POSTN) participates in pathophysiological processes such as glucolipid metabolic disorders and insulin resistance, and is closely associated with the development and progression of diabetes-related kidney disease. It reviews the relationship and mechanisms between periostin and type 2 diabetes-related kidney disease, aiming to provide new evidence for the diagnosis and treatment of DKD.
文章引用：王欣, 孙文学, 马晓庆. 骨膜蛋白在2型糖尿病肾病中的作用研究进展[J]. 临床医学进展, 2026, 16(6): 602-609. https://doi.org/10.12677/acm.2026.1662257

参考文献

[1] (2021) The Prevention of Diabetes Mellitus. JAMA, 325, 190.
[2] Accili, D., Deng, Z. and Liu, Q. (2025) Insulin Resistance in Type 2 Diabetes Mellitus. Nature Reviews Endocrinology, 21, 413-426. [Google Scholar] [CrossRef] [PubMed]
[3] 杜晓洋, 刘昊凌. 骨膜蛋白与代谢相关性疾病的关系[J]. 医学综述, 2017, 23(15): 2913-2917.
[4] Sen, K., Lindenmeyer, M.T., Gaspert, A., Eichinger, F., Neusser, M.A., Kretzler, M., et al. (2011) Periostin Is Induced in Glomerular Injury and Expressed De Novo in Interstitial Renal Fibrosis. The American Journal of Pathology, 179, 1756-1767. [Google Scholar] [CrossRef] [PubMed]
[5] Takeshita, S., Kikuno, R., Tezuka, K. and Amann, E. (1993) Osteoblast-Specific Factor 2: Cloning of a Putative Bone Adhesion Protein with Homology with the Insect Protein Fasciclin I. Biochemical Journal, 294, 271-278. [Google Scholar] [CrossRef] [PubMed]
[6] Horiuchi, K., Amizuka, N., Takeshita, S., Takamatsu, H., Katsuura, M., Ozawa, H., et al. (1999) Identification and Characterization of a Novel Protein, Periostin, with Restricted Expression to Periosteum and Periodontal Ligament and Increased Expression by Transforming Growth Factor β. Journal of Bone and Mineral Research, 14, 1239-1249. [Google Scholar] [CrossRef] [PubMed]
[7] Thapa, N., Lee, B. and Kim, I. (2007) TGFBIp/betaig-h3 Protein: A Versatile Matrix Molecule Induced by TGF-beta. The International Journal of Biochemistry & Cell Biology, 39, 2183-2194. [Google Scholar] [CrossRef] [PubMed]
[8] Xiong, X., Feng, X. and Ding, Y. (2024) Periostin Induces Epithelial‐Mesenchymal Transition via p38-MAPK Pathway in Human Renal Tubular Cells by High Glucose. Immunity, Inflammation and Disease, 12, e70077. [Google Scholar] [CrossRef] [PubMed]
[9] Turczyn, A. and Pańczyk-Tomaszewska, M. (2021) The Role of Periostin in Kidney Diseases. Central European Journal of Immunology, 46, 494-501. [Google Scholar] [CrossRef] [PubMed]
[10] Kii, I. (2019) Practical Application of Periostin as a Biomarker for Pathological Conditions. In: Kudo, A., Ed., Periostin, Springer, 195-204. [Google Scholar] [CrossRef] [PubMed]
[11] Satirapoj, B., Tassanasorn, S., Charoenpitakchai, M. and Supasyndh, O. (2015) Periostin as a Tissue and Urinary Biomarker of Renal Injury in Type 2 Diabetes Mellitus. PLOS ONE, 10, e0124055. [Google Scholar] [CrossRef] [PubMed]
[12] 骆媛媛, 邓华聪. 骨膜蛋白在代谢相关性疾病中的研究进展[J]. 重庆医科大学学报, 2016, 41(4): 429-432.
[13] Lu, Y., Liu, X., Jiao, Y., Xiong, X., Wang, E., Wang, X., et al. (2014) Periostin Promotes Liver Steatosis and Hypertriglyceridemia through Downregulation of PPARα. Journal of Clinical Investigation, 124, 3501-3513. [Google Scholar] [CrossRef] [PubMed]
[14] Bolton, K., Segal, D., McMillan, J., Sanigorski, A., Collier, G. and Walder, K. (2009) Identification of Secreted Proteins Associated with Obesity and Type 2 Diabetes in Psammomys Obesus. International Journal of Obesity, 33, 1153-1165. [Google Scholar] [CrossRef] [PubMed]
[15] Zhu, J.Z., Zhu, H.T., Dai, Y.N., et al. (2016) Serum Periostin Is a Potential Biomarker for Non-Alcoholic Fatty Liver Disease: A Case-Control Study. Endocrine, 51, 91-100. [Google Scholar] [CrossRef] [PubMed]
[16] Amara, S., Lopez, K., Banan, B., Brown, S., Whalen, M., Myles, E., et al. (2015) Synergistic Effect of Pro-Inflammatory TNFα and IL-17 in Periostin Mediated Collagen Deposition: Potential Role in Liver Fibrosis. Molecular Immunology, 64, 26-35. [Google Scholar] [CrossRef] [PubMed]
[17] Ji, Q., Li, X., Wang, Y., Liu, H., Chen, K., Quan, H., et al. (2023) Periostin Acts as a Bridge between Gestational Diabetes Mellitus (GDM) and Chronic Inflammation to Modulate Insulin Resistance by Modulating PPARα/NF-κB/TNF-α Signaling Pathway. Endocrine, Metabolic & Immune Disorders—Drug Targets, 23, 1649-1659. [Google Scholar] [CrossRef] [PubMed]
[18] Luo, Y., Qu, H., Wang, H., Wei, H., Wu, J., Duan, Y., et al. (2016) Plasma Periostin Levels Are Increased in Chinese Subjects with Obesity and Type 2 Diabetes and Are Positively Correlated with Glucose and Lipid Parameters. Mediators of Inflammation, 2016, Article ID: 6423637. [Google Scholar] [CrossRef] [PubMed]
[19] 罗俊婷, 胡欣, 陈国芳, 等. 骨膜蛋白与代谢性疾病[J]. 国际内分泌代谢杂志, 2018, 38(1): 26-28.
[20] Cho, A., Jin, W., Lee, J., Shin, N., Lee, M.S., Li, L., et al. (2023) Periostin Deficiency Attenuates Kidney Fibrosis in Diabetic Nephropathy by Improving Pancreatic β-Cell Dysfunction and Reducing Kidney EMT. Scientific Reports, 13, Article No. 17599. [Google Scholar] [CrossRef] [PubMed]
[21] Ina, K., Kitamura, H., Tatsukawa, S., Takayama, T., Fujikura, Y. and Shimada, T. (2002) Transformation of Interstitial Fibroblasts and Tubulointerstitial Fibrosis in Diabetic Nephropathy. Medical Electron Microscopy, 35, 87-95. [Google Scholar] [CrossRef] [PubMed]
[22] Brosius, F.C., Khoury, C.C., Buller, C.L. and Chen, S. (2010) Abnormalities in Signaling Pathways in Diabetic Nephropathy. Expert Review of Endocrinology & Metabolism, 5, 51-64. [Google Scholar] [CrossRef] [PubMed]
[23] Prakoura, N., Kavvadas, P., Kormann, R., Dussaule, J., Chadjichristos, C.E. and Chatziantoniou, C. (2017) NF-κB-Induced Periostin Activates Integrin-β3 Signaling to Promote Renal Injury in GN. Journal of the American Society of Nephrology, 28, 1475-1490. [Google Scholar] [CrossRef] [PubMed]
[24] Hwang, J.H., Yang, S.H., Kim, Y.C., Kim, J.H., An, J.N., Moon, K.C., et al. (2017) Experimental Inhibition of Periostin Attenuates Kidney Fibrosis. American Journal of Nephrology, 46, 501-517. [Google Scholar] [CrossRef] [PubMed]
[25] Guerrot, D., Dussaule, J., Mael-Ainin, M., Xu-Dubois, Y., Rondeau, E., Chatziantoniou, C., et al. (2012) Identification of Periostin as a Critical Marker of Progression/Reversal of Hypertensive Nephropathy. PLOS ONE, 7, e31974. [Google Scholar] [CrossRef] [PubMed]
[26] Ito, T., Suzuki, A., Imai, E., Horimoto, N., Ohnishi, T., Daikuhara, Y., et al. (2002) Tornado Extraction: A Method to Enrich and Purify RNA from the Nephrogenic Zone of the Neonatal Rat Kidney. Kidney International, 62, 763-769. [Google Scholar] [CrossRef] [PubMed]
[27] Wallace, D.P. (2019) Periostin in the Kidney. In: Kudo, A., Ed., Periostin, Springer, 99-112. [Google Scholar] [CrossRef] [PubMed]
[28] Abbad, L., Prakoura, N., Michon, A., Chalghoumi, R., Reichelt-Wurm, S., Banas, M.C., et al. (2022) Role of Periostin and Nuclear Factor-κB Interplay in the Development of Diabetic Nephropathy. Cells, 11, Article No. 2212. [Google Scholar] [CrossRef] [PubMed]
[29] Varatharajan, S., Jain, V., Pyati, A.K., Neeradi, C., Reddy, K.S., Pallavali, J.R., et al. (2024) Neutrophil Gelatinase-Associated Lipocalin, Kidney Injury Molecule-1, and Periostin: Novel Urinary Biomarkers in Diabetic Nephropathy. World Journal of Nephrology, 13, Article No. 98880. [Google Scholar] [CrossRef] [PubMed]
[30] Satirapoj, B., Wang, Y., Chamberlin, M.P., Dai, T., LaPage, J., Phillips, L., et al. (2012) Periostin: Novel Tissue and Urinary Biomarker of Progressive Renal Injury Induces a Coordinated Mesenchymal Phenotype in Tubular Cells. Nephrology Dialysis Transplantation, 27, 2702-2711. [Google Scholar] [CrossRef] [PubMed]
[31] Mael-Ainin, M., Abed, A., Conway, S.J., Dussaule, J. and Chatziantoniou, C. (2014) Inhibition of Periostin Expression Protects against the Development of Renal Inflammation and Fibrosis. Journal of the American Society of Nephrology, 25, 1724-1736. [Google Scholar] [CrossRef] [PubMed]
[32] El-Dawla, N.M.Q., Sallam, A.M., El-Hefnawy, M.H. and El-Mesallamy, H.O. (2019) E-Cadherin and Periostin in Early Detection and Progression of Diabetic Nephropathy: Epithelial-to-Mesenchymal Transition. Clinical and Experimental Nephrology, 23, 1050-1057. [Google Scholar] [CrossRef] [PubMed]
[33] Ziyadeh, F.N. (2004) Mediators of Diabetic Renal Disease: The Case for TGF-Beta as the Major Mediator. Journal of the American Society of Nephrology, 15, S55-S57. [Google Scholar] [CrossRef] [PubMed]
[34] Reidy, K. and Susztak, K. (2009) Epithelial-Mesenchymal Transition and Podocyte Loss in Diabetic Kidney Disease. American Journal of Kidney Diseases, 54, 590-593. [Google Scholar] [CrossRef] [PubMed]
[35] Ibrahim, H.M., Ali, S.A., Ramzy, T.A., Elsaid, N.H. and Shaker, A.M. (2025) Role of Serum Periostin Level as Profibrotic Marker in Conjunction with Renal Resistivity Index and Shear Wave Elastography in Predicting Renal Fibrosis in Diabetic Nephropathy. BMC Nephrology, 26, Article No. 682. [Google Scholar] [CrossRef] 
[36] Lim, A. (2014) Diabetic Nephropathy—Complications and Treatment. International Journal of Nephrology and Renovascular Disease, 7, 361-381. [Google Scholar] [CrossRef] [PubMed]
[37] Aghamir, S.M.K., Amiri, M., Panahi, G., Khatami, F., Dehghani, S. and Moosavi, M. (2023) Salivary and Serum Periostin in Kidney Transplant Recipients. PLOS ONE, 18, e0285256. [Google Scholar] [CrossRef] [PubMed]
[38] Um, J.E., Park, J.T., Nam, B.Y., Lee, J.P., Jung, J.H., Kim, Y., et al. (2017) Periostin-Binding DNA Aptamer Treatment Attenuates Renal Fibrosis under Diabetic Conditions. Scientific Reports, 7, Article No. 8490. [Google Scholar] [CrossRef] [PubMed]

为你推荐